Equity Research
William Blair research analyst Tim Lugo was quoted in this Barron’s article discussing Sarepta Therapeutics and the intersection of approvals for its new gene therapy drug and a recent decline in the stock price.
“We continue to believe that SRP-9001 represents both a meaningful therapy for patients and significant opportunity for Sarepta,” his research note said.
Stay up-to-date with the latest William Blair news and insights
William Blair acted as the exclusive financial advisor to Duomed Group, a portfolio company of G Square Healthcare Private Equity, in connection with the contemplated sale to Palex Medical, a portfolio company of Apax Partners and Fremman Capital.
Read moreAbsent further legislation, The Tax Cuts and Jobs Act will sunset on January 1, 2026, reverting to 2017 levels, adjusted for inflation, or approximately $7M per taxpayer. As a result, wealthy individuals and families will be subject to significantly more federal estate tax in 2026 than they are today.
Read moreUnderstanding the nuances between retirement plans can be challenging. William Blair’s Quick Reference Guide to Retirement Plans compares and contrasts features such as account establishment, account contributions, and accessibility.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
